Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19088342 | 0.87 | NAAA (0.37) | NAAACYP2C19CYP19A1TSHRTP53 | |
| SCHEMBL16837528 | 0.85 | NAAA (0.46) | NAAAALDH1A1NLRP3CYP2C19CYP19A1 | |
| SCHEMBL8059341 | 0.83 | NAAA (0.50) | NAAAALDH1A1NLRP3CYP2C19CYP19A1 | |
| SCHEMBL28869002 | 0.81 | NAAA (0.49) | NAAAALDH1A1NLRP3CYP2C19CYP19A1 | |
| SCHEMBL18827874 | 0.80 | NAAA (0.42) | NAAAALDH1A1NLRP3CYP2C19TSHR | |
| SCHEMBL8690677 | 0.78 | — | — | |
| SCHEMBL1695592 | 0.75 | NAAA (0.72) | NAAAALDH1A1CYP2C19CYP19A1TSHR | |
| SCHEMBL2433610 | 0.75 | NAAA (0.67) | NAAAALDH1A1CYP2C19CYP19A1TSHR | |
| SCHEMBL21765705 | 0.75 | NAAA (0.49) | NAAAALDH1A1CYP2C19CYP19A1TSHR | |
| SCHEMBL10929265 | 0.73 | NAAA (0.55) | NAAAALDH1A1CYP2C19CYP19A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472392-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2019-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472392-B2 | Macrocyclic inhibitors of flaviviridae viruses | HAVCR2, ZC3HAV1, HCCS | NAAA 2162/4885ALDH1A1 1076/4885NLRP3 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.